baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

IDORSIA N/ CH0363463438 /

11/11/2024 13:44:54	Chg. -0.1210	Volume	Bid13:44:54	Ask13:44:54	Market Capitalization	Dividend Y.	P/E Ratio
0.9540CHF	-11.26%	1.05 mill. Turnover: 1.02 mill.	0.9480Bid Size: 3,500	0.9675Ask Size: 7,793	179.72 mill.CHF	-	-

GlobeNewswire 13/08 Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026

GlobeNewswire 09/08 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...

GlobeNewswire 24/06 Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

GlobeNewswire 18/06 Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow ...

GlobeNewswire 22/05 Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire 09/05 Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024

GlobeNewswire 17/04 Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determ...

GlobeNewswire 01/04 Nxera Pharma is the New Name for Sosei Group

GlobeNewswire 27/03 Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of C...

GlobeNewswire 28/02 Idorsia and Viatris enter into a significant global research and development collaboration

GlobeNewswire 16/02 Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Offic...

GlobeNewswire 13/02 Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

GlobeNewswire 22/01 Sosei Heptares Webinar Presentation for FY2023 Financial Results

GlobeNewswire 05/01 Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief O...

GlobeNewswire 07/12/2023 Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

GlobeNewswire 15/11/2023 Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

GlobeNewswire 10/11/2023 Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine ...

GlobeNewswire 03/11/2023 New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at th...

GlobeNewswire 31/10/2023 Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), ...

GlobeNewswire 25/10/2023 Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress

GlobeNewswire 16/10/2023 CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire 11/09/2023 Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Of...

GlobeNewswire 28/02/2022 Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference

GlobeNewswire 17/02/2022 Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

GlobeNewswire 08/02/2022 Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profit...

IDORSIA N/ CH0363463438 /

If you wish to receive reply to your feedback, please provide your email address.